AI assistant
Karo Pharma AB — Share Issue/Capital Change 2015
May 29, 2015
6166_rns_2015-05-29_24d4cc53-e3c4-4ef1-abaa-62be9a4a54a0.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Change of the number of shares and votes in Karo Bio AB (publ)
STOCKHOLM, May 29, 2015 - Karo Bio AB (publ) today announced that the company's total number of shares as per May 29, 2015 amounts to 689,743,550 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the recently completed acquisition of 100% of the shares in Tanomed AB and the directed new share issue of 13,480,392 shares to the shareholders in Tanomed AB.
For further information, please contact:
Henrik Palm, CFO, telephone +46 70 540 4014 or email [email protected]
About Karo Bio
Karo Bio is a development company focused on broadening its operations to include projects and products closer to market. Karo Bio has several projects approaching clinical phase. Karo Bio is based in Huddinge, Sweden and is listed on Nasdaq Stockholm.
Karo Bio publishes this information in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication on May 29, 2015 at 8:30 CET.
This press release is also available on www.karobio.se and www.newsroom.cision.com.